Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Prescription Drug Monitoring Programs and Opioid Death Rates

Prescription Drug Monitoring Programs and Opioid Death Rates Letters assure safety or efficacy of PAP for the prevention of cardio- Noting “[state] policies have been shown to reduce the vascular events. Likewise, posthoc analyses of selected inter- amount of opioids prescribed, prescription opioid–involved mediate outcomes are a weak basis for defining benefit or overdose deaths, and all opioid-involved deaths” suggests harm for clinical outcomes. There are many examples of dis- that a causal relationship exists between the implementation eases for which observational findings have been shown to of state policies and a decrease in opioid death rates. This be inconsistent with trial results, even when clear benefits on claim was based on data collected between 2006 and 2013 intermediate risk markers have been demonstrated for inter- from Kentucky, Ohio, Tennessee, and West Virginia. Of the 4 ventions. In diabetes, for example, the withdrawal from the states examined, only Kentucky and West Virginia showed a market of agents found initially to produce favorable effects decrease in deaths due to prescription opioids from 2011 to on glycemia but ultimately to cause harmful effects on car- 2015. However, all 4 states have seen an increase in overall diovascular outcomes has resulted in an entirely new regula- opioid-involved deaths from 2011 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Prescription Drug Monitoring Programs and Opioid Death Rates

JAMA , Volume 318 (20) – Nov 28, 2017

Loading next page...
 
/lp/american-medical-association/prescription-drug-monitoring-programs-and-opioid-death-rates-MywRYxDfH1
Publisher
American Medical Association
Copyright
Copyright 2017 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2017.16300
pmid
29183062
Publisher site
See Article on Publisher Site

Abstract

Letters assure safety or efficacy of PAP for the prevention of cardio- Noting “[state] policies have been shown to reduce the vascular events. Likewise, posthoc analyses of selected inter- amount of opioids prescribed, prescription opioid–involved mediate outcomes are a weak basis for defining benefit or overdose deaths, and all opioid-involved deaths” suggests harm for clinical outcomes. There are many examples of dis- that a causal relationship exists between the implementation eases for which observational findings have been shown to of state policies and a decrease in opioid death rates. This be inconsistent with trial results, even when clear benefits on claim was based on data collected between 2006 and 2013 intermediate risk markers have been demonstrated for inter- from Kentucky, Ohio, Tennessee, and West Virginia. Of the 4 ventions. In diabetes, for example, the withdrawal from the states examined, only Kentucky and West Virginia showed a market of agents found initially to produce favorable effects decrease in deaths due to prescription opioids from 2011 to on glycemia but ultimately to cause harmful effects on car- 2015. However, all 4 states have seen an increase in overall diovascular outcomes has resulted in an entirely new regula- opioid-involved deaths from 2011

Journal

JAMAAmerican Medical Association

Published: Nov 28, 2017

References